Cheminformatics and virtual screening studies of COMT inhibitors as potential Parkinson’s disease therapeutics

References

• Axelrod J, Tomchick R. Enzymatic O-methylation of epinephrine and other catechols. J Biol Chem. 1958;233:702–705.
   PubMed Web of Science ®Google Scholar
• Guldberg HC, Marsden CA. Catechol-O-methyl transferase: pharmacological aspects and physiological role. Pharmacol Rev. 1975;27:135–206.
   PubMed Web of Science ®Google Scholar
• Mannisto PT, Kaakkola S. Catechol-O-methyltransferase (COMT): biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective comt inhibitors. Pharmacol Rev. 1999;51:593–628.
   Google Scholar
• Lotta T, Vidgren J, Tilgmann C, et al. Kinetics of human soluble and membrane-bound catechol O-methyltransferase: a revised mechanism and description of the thermolabile variant of the enzyme. Biochemistry. 1995;34:4202–4210.
   PubMed Web of Science ®Google Scholar
• Tenhunen J, Salminen M, Lundström K, et al. Genomic organization of the human catechol O-methyltransferase gene and its expression from two distinct promoters. Eur J Biochem. 1994;223:1049–1059.
   PubMedGoogle Scholar
• Karhunen T, Tilgmann C, Ulmanen I, et al. Distribution of catechol-O-methyltransferase enzyme in rat tissues. J Histochem Cytochem. 1994;42:1079–1090.
   PubMed Web of Science ®Google Scholar
• Orłowski A, St-Pierre JF, Magarkar A, et al. Properties of the membrane binding component of catechol-o-methyltransferase revealed by atomistic molecular dynamics simulations. J Phys Chem B. 2011;115:13541–13550.
   PubMed Web of Science ®Google Scholar
• Kostic VS. COMT inhibition in the treatment of Parkinson’s disease: neuroprotection and future perspectives. Adv Exp Med Biol. 2004;541:75–90.
   PubMed Web of Science ®Google Scholar
• Bonifacio JM, Palma N, Almeida L, et al. Catechol-O-methyltransferase and its inhibitors in Parkinson’s disease. CNS Drug Rev. 2007;13:352–379.
   PubMedGoogle Scholar
• Bakke OM. O-methylation of simple phenols in the rat. Acta Pharmacol Toxicol. 1970;28(1):28–38.
   PubMedGoogle Scholar
• Bonifacio MJ, Torrao L, Wright L, et al. Membrane-bound COMT inhibition by nebicapone. Faseb J. 2007;21(804):3.
   Google Scholar
• Dingemanse J, Jorga K, Zurcher G, et al. Pharmacokinetic-pharmacodynamic interaction between the COMT inhibitor tolcapone and single-dose levodopa. Br J Pharmacol. 1995;40:253–262.
   Web of Science ®Google Scholar
• Haasio C. Toxicology and safety of COMT inhibitors. Int Rev Neurobiol. 2010;95:163–189.
   PubMed Web of Science ®Google Scholar
• Lerner C, Ruf A, Gramlich V, et al. X-ray crystal structure of a bisubstrate inhibitor bound to the enzyme catechol-O-methyltransferase: A dramatic effect of inhibitor preorganization on binding affinity. Angew Chem Int Ed Engl. 2001;40:4040–4042.
   Web of Science ®Google Scholar
• Masjost B, Ballmer P, Borroni E, et al. Structure-based design, synthesis, and in vitro evaluation of bisubstrate inhibitors for catechol O-methyltransferase (COMT). Chemistry. 2000;6:971–982.
   PubMed Web of Science ®Google Scholar
• Vidgren J, Svensson LA, Liljas A. Crystal structure of catechol Omethyltransferase. Nature. 1994;368:354–358.
   PubMed Web of Science ®Google Scholar
• Rutherford K, Le Trong I, Stenkamp RE, et al. Crystal structures of human 108 V and 108 M catechol O-methyltransferase. J Mol Biol. 2008;380:120–130.
   PubMed Web of Science ®Google Scholar
• Bonifacio MJ, Archer M, Rodrigues ML, et al. Kinetics and crystal structure of catechol-O-methyltransferase complex with co-substrate and a novel inhibitor with potential therapeutic application. Mol Pharmacol. 2002;62:795–805.
   PubMed Web of Science ®Google Scholar
• Zheng YJ, Bruice TC. A theoretical examination of the factors controlling the catalytic efficiency of a transmethylation enzyme: catechol O-methyltransferase. J Am Chem Soc. 1997;119:8137–8145.
   Web of Science ®Google Scholar
• Woodard RW, Tsai MD, Floss HG, et al. Stereochemical course of the transmethylation catalyzed by catechol-O-methyltransferase. J Biol Chem. 1980;255:9124–9127.
   PubMed Web of Science ®Google Scholar
• Vidgren J. X-ray crystallography of catechol O-methyltransferase: perspectives for target-based drug development. Adv Pharmacol. 1997;42:238–331.
   Google Scholar
• Jeffery DR, Roth JA. Kinetic reaction mechanism for magnesium binding to membrane-bound and soluble catechol-O-methyltransferase. Biochemistry. 1987;26:2955–2958.
   PubMed Web of Science ®Google Scholar
• Lau EY, Bruice TC. Importance of correlated motions in forming highly reactive near attack conformations in catechol-O-methyltransferase. J Am Chem Soc. 1998;120:12387–12394.
   Web of Science ®Google Scholar
• Kuhn B, Kollman PA. QM-FE and molecular dynamics calculations on catechol-O-methyltransferase: free energy of activation in the enzyme and in aqueous solution and regioselectivity of the enzyme-catalyzed reaction. J Am Chem Soc. 2000;122:2586–2596.
   Web of Science ®Google Scholar
• Lautala P, Ulmanen I, Taskinen J. Molecular mechanisms controlling the rate and specificity of catechol-O-methylation by human soluble catechol-O-methyltransferase. Mol Pharmacol. 2001;59:393–402.
   PubMed Web of Science ®Google Scholar
• Chen D, Wang CY, Lambert DJ, et al. Inhibition of human liver catechol-O-methyltransferase by tea catechins and their metabolites: structure–activity relationship and molecular-modeling studies. Biochem Pharmacol. 2005;69:1523–1531.
   PubMed Web of Science ®Google Scholar
• Azam F, Mohamed N, Alhussen F. Molecular interaction studies of green tea catechins as multitarget drug candidates for the treatment of Parkinson’s disease: computational and structural insights. Network Comput Neural Syst. 2015;26:97–115.
   PubMed Web of Science ®Google Scholar
• Cao Y, Chen ZJ, Jiang HD, et al. computational studies of the regioselectivities of comt-catalyzed meta-/para-O methylations of luteolin and quercetin. J Phys Chem B. 2014;118:470−481.
   PubMed Web of Science ®Google Scholar
• Zhu BT, Ezell EL, Liehr JG. Catechol-O- methyltransferase-catalyzed rapid O-methylation of mutagenic flavonoids. Metabolic inactivation as a possible reason for their lack of carcinogenicity in vivo. J. Biol. Chem. 1994;269:292−299.
   PubMed Web of Science ®Google Scholar
• Nagappan P, Krishnamurthy V. structural prediction and comparative molecular docking studies of hesperidin and l-dopa on α-synuclein, MAO-B, COMT and UCHL-1 inhibitors. Int J Pharm Clin Res. 2015;7:221–225.
   Google Scholar
• Monteiro A, Viana J, Nayarisseri A, et al. computational studies applied to flavonoids against Alzheimer’s and Parkinson’s diseases. Hindawi Oxid Med Cell Longevity. 2018;2:1–21.
   Google Scholar
• Palma PN, Bonifacio MJ, Loureiro AI, et al. Molecular modeling and metabolic studies of the interaction of catechol-O-methyltransferase and a new nitrocatechol inhibitor. Drug Metab Dispos. 2003;31:250–258.
   PubMed Web of Science ®Google Scholar
• Soares-da-Silva P, Vieira-Coelho MA, Parada A. Catechol-O-methyltransferase inhibition in erythrocytes and liver by BIA 3–202 (1-[3,4-dibydroxy-5-nitrophenyl]-2-phenyl-ethanone). Pharmacol Toxicol. 2003;92:272–278.
   PubMedGoogle Scholar
• Palma PN, Rodrigues ML, Archer M, et al. Comparative study of ortho- and meta-nitrated inhibitors of catechol-O-methyltransferase: interactions with the active site and regioselectivity of O-methylation. Mol Pharmacol. 2006;70:143–153.
   PubMed Web of Science ®Google Scholar
• Learmonth DA, Palma PN, Vieira-Coelho MA, et al. Synthesis, biological evaluation, and molecular modeling studies of a novel, peripherally selective inhibitor of catechol-O-methyltransferase. J Med Chem. 2004;47:6207–6217.
   PubMedGoogle Scholar
• Lee JY, Baek S, Kim Y. Receptor-oriented pharmacophore-based in silico screening of human catechol O-methyltransferase for the design of antiparkinsonian drug. B Korean Chem Soc. 2007;28:379–385.
   Web of Science ®Google Scholar
• Paulini R, Lerner C, Jakob-Roetne R, et al. Bisubstrate inhibitors of the enzyme catechol O-methyltransferase (COMT): efficient inhibition despite the lack of a nitro group. Chembiochem. 2004;5:1270–1274.
   PubMed Web of Science ®Google Scholar
• Smith KS, Smith PL, Heady TN, et al. In vitro metabolism of tolcapone to reactive intermediates: relevance to tolcapone liver toxicity. Chem Res Toxicol. 2003;16:123–128.
   PubMed Web of Science ®Google Scholar
• Ellermann M, Jakob-Roetne R, Lerner C, et al. Molecular recognition at the active site of catechol-O-methyltransferase: energetically favorable replacement of a water molecule imported by a bisubstrate inhibitor. Angew Chem Int Ed Engl. 2009;48:9092–9096.
   PubMed Web of Science ®Google Scholar
• Ellermann M, Paulini R, Jakob-Roetne R, et al. Molecular recognition at the active site of catechol-O-methyltransferase (COMT): adenine replacements in bisubstrate inhibitors. Chemistry. 2011;17:6369–6381.
   PubMed Web of Science ®Google Scholar
• Mazumber KM, Bhaltacharjee N, Borah A. Garcinol prevents hyperhomocysteinemia and enhances bioavailability of L-DOPA by inhibiting catechol-O-methyltransferase: an in silico approach. Med Chem Res. 2016;25:116–122.
   Web of Science ®Google Scholar
• Masullo M, Bassarello C, Suzuki H, et al. Polyisoprenylated benzophenones and an unusual polyisopreny- lated tetracyclic xanthone from the fruits of Garcinia cambogia. J Agric Food Chem. 2008;56:5205–5210.
   PubMed Web of Science ®Google Scholar
• Hong J, Sang S, Park HJ, et al. Modulation of arachidonic acid metabolism and nitric oxide synthesis by garcinol and its derivatives. Carcinogenesis. 2006;27:278–286.
   PubMed Web of Science ®Google Scholar
• Liao CH, Ho CT. Lin JK effects of garcinol on free radical generation and NO production in embryonic rat cortical neurons and astrocytes. Biochem Biophys Res Commun. 2005;329:1306–1314.
   PubMed Web of Science ®Google Scholar
• Deba S, Phukana BC, Mazumder KM, et al. Garcinol, a multifaceted sword for the treatment of Parkinson’s disease. Neurochem Int. 2019;128:50–57.
   PubMed Web of Science ®Google Scholar
• Troen AM. The central nervous system in animal models of hyperhomocysteinemia. Prog Neuropsychopharmacol Biol Psychiatry. 2005;29:1140–1151.
   PubMed Web of Science ®Google Scholar
• Tsuji E, Okazaki K, Takeda K. Crystal structures of rat catechol-O-methyltransferase complexed with coumarine-based inhibitor. Biochem Biophys Res Commun. 2009;378:494–497.
   PubMed Web of Science ®Google Scholar
• Kiss LE, Ferreira HS, Torrao L, et al. Discovery of a long-acting, peripherally selective inhibitor of catechol-O-methyltransferase. J Med Chem. 2010;53:3396–3411.
   PubMed Web of Science ®Google Scholar
• Jatana N, Sharma A, Latha N. Pharmacophore modeling and virtual screening studies to design potential COMT inhibitors as new leads. J Mol Graph Model. 2013;39:145–164.
   Google Scholar
• Palma PN, Bonifacio MJ, Loureiro AI, et al. Computation of the binding affinities of catechol-O-methyltransferase inhibitors: multisubstate relative free energy calculations. J Comput Chem. 2012;33:970–986.
   PubMed Web of Science ®Google Scholar
• Magarkar A, Parkkila P, Viitala T, et al. Membrane bound COMT isoform is an interfacial enzyme: general mechanism, new drug design paradigm. Chem Comm. 2018;54:3440–3443.
   PubMed Web of Science ®Google Scholar
• Savelieff MG, Nam G, Kang J, et al. Development of multifunctional molecules as potential therapeutic candidates for Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis in the last decade. Chem Rev. 2019;119:1221–1332.
   PubMed Web of Science ®Google Scholar
• Aarthy M, Panwar U, Selvaraj C, et al. Advantages of structure-based drug design approaches in neurological disorders. Curr Neuropharmacol. 2017;15:1136–1155.
   PubMed Web of Science ®Google Scholar
• Patel N, Georrge J, Modi K, et al. Pharmacophore-based virtual screening of catechol-o-methyltransferase (COMT) inhibitors to combat Alzheimer’s disease. J Biomol Struct Dyn. 2017;36:3938–3957.
   PubMed Web of Science ®Google Scholar
• Fredriksson A, Archer T. Synergetic interactions between COMT-/MAO- inhibitors and L-Dopa in MPTP-treated mice. J Neural Transm Gen. 1995;102:19–34.
   PubMed Web of Science ®Google Scholar
• Lyytinen J, Kaakkola S, Ahtila S, et al. Simultaneous MAO-B and COMT inhibition in L-DOPA- treated patients with Parkinson’s disease. Mov Disord. 1997;12:497–505.
   PubMed Web of Science ®Google Scholar
• Talati R, Reinhart K, Baker W, et al. Pharmacological treatment of advanced Parkinson’s desease: A meta-analysis of COMT inhibitors and MAO-B inhibitors. Parkinsonism Related Dicord. 2009;15:500–505.
   PubMed Web of Science ®Google Scholar
• Khromova I, Voronina T, Kraineva VA, et al. Effects of selective catechol-O-methyltransferase inhibitors on single-trial passive avoidance retention in male rats. Behav Brain Res. 1997;86:49–57.
   PubMed Web of Science ®Google Scholar
• Moreau JL, Borgulya J, Jenck F, et al. Tolcapone: a potential new antidepressant detected in a novel animal model of depression. Behav Pharmacol. 1994;5:344–350.
   PubMed Web of Science ®Google Scholar
• Gasparini M, Fabrizio E, Bonifati V, et al. Cognitive improvement during tolcapone treatment in parkinson’s disease. J Neural Transm. 1997;104:887–894.
   PubMed Web of Science ®Google Scholar